Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so

This article was originally published in Scrip

Executive Summary

AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEGASUS clinical trial, but analysts and doctors are concerned about the bleeding risk associated with the drug.

You may also be interested in...



AstraZeneca Groomed Paul Hudson For His New Role … At Novartis

Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.

CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure

Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody. 

Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds

Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC028114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel